Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1882 1
1886 1
1946 1
1948 1
1949 1
1950 3
1951 3
1952 1
1955 2
1957 6
1958 1
1962 1
1963 2
1964 1
1965 1
1966 1
1968 1
1970 4
1971 3
1972 1
1973 1
1974 5
1975 8
1976 8
1977 7
1978 4
1979 9
1980 8
1981 9
1982 9
1983 11
1984 6
1985 14
1986 10
1987 10
1988 6
1989 7
1990 7
1991 14
1992 11
1993 9
1994 15
1995 15
1996 11
1997 19
1998 20
1999 16
2000 24
2001 23
2002 24
2003 17
2004 19
2005 18
2006 19
2007 39
2008 24
2009 33
2010 41
2011 38
2012 45
2013 55
2014 80
2015 81
2016 94
2017 86
2018 72
2019 79
2020 80
2021 113
2022 83
2023 95
2024 42

Text availability

Article attribute

Article type

Publication date

Search Results

1,498 results

Results by year

Filters applied: . Clear all
Page 1
Telomeres Fuse During Cardiomyocyte Maturation.
Aix E, Gallinat A, Yago-Díez C, Lucas J, Gómez MJ, Benguría A, Freitag P, Cortez-Toledo E, Fernández de Manuel L, García-Cuasimodo L, Sánchez-Iranzo H, Montoya MC, Dopazo A, Sánchez-Cabo F, Mercader N, López JE, Fleischmann BK, Hesse M, Flores I. Aix E, et al. Among authors: lucas j. Circulation. 2023 May 23;147(21):1634-1636. doi: 10.1161/CIRCULATIONAHA.122.062229. Epub 2023 May 22. Circulation. 2023. PMID: 37216436 No abstract available.
A roadmap during parenting.
Lucas TL. Lucas TL. Lancet Haematol. 2022 Sep;9(9):e644. doi: 10.1016/S2352-3026(22)00262-9. Lancet Haematol. 2022. PMID: 36055330 No abstract available.
Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers.
Pittet LF, Messina NL, Orsini F, Moore CL, Abruzzo V, Barry S, Bonnici R, Bonten M, Campbell J, Croda J, Dalcolmo M, Gardiner K, Gell G, Germano S, Gomes-Silva A, Goodall C, Gwee A, Jamieson T, Jardim B, Kollmann TR, Lacerda MVG, Lee KJ, Lucas M, Lynn DJ, Manning L, Marshall HS, McDonald E, Munns CF, Nicholson S, O'Connell A, de Oliveira RD, Perlen S, Perrett KP, Prat-Aymerich C, Richmond PC, Rodriguez-Baño J, Dos Santos G, da Silva PV, Teo JW, Villanueva P, Warris A, Wood NJ, Davidson A, Curtis N; BRACE Trial Consortium Group. Pittet LF, et al. Among authors: lucas m. N Engl J Med. 2023 Apr 27;388(17):1582-1596. doi: 10.1056/NEJMoa2212616. N Engl J Med. 2023. PMID: 37099341 Free PMC article. Clinical Trial.
RNA Therapeutics in Cardiovascular Disease.
Lucas T, Bonauer A, Dimmeler S. Lucas T, et al. Circ Res. 2018 Jul 6;123(2):205-220. doi: 10.1161/CIRCRESAHA.117.311311. Circ Res. 2018. PMID: 29976688 Review.
Vancomycin therapeutic drug monitoring in paediatrics.
Patel J, Lucas CJ, Ryan J, Jenkins M, Martin JH. Patel J, et al. Among authors: lucas cj. J Paediatr Child Health. 2020 Apr;56(4):563-570. doi: 10.1111/jpc.14683. Epub 2019 Nov 13. J Paediatr Child Health. 2020. PMID: 31721353 Review.
Primary outcome measures were vancomycin initial dose (mg/kg/day) and the timing and result of first trough concentration (mg/L). Secondary outcome measures were the numbers achieving recommended targets and whether appropriate dose adjustments were made in response to TDM …
Primary outcome measures were vancomycin initial dose (mg/kg/day) and the timing and result of first trough concentration (mg/L). Sec …
Dealing with a changing medical landscape.
Lucas TL. Lucas TL. Lancet Haematol. 2023 Jun;10(6):e402. doi: 10.1016/S2352-3026(23)00122-9. Lancet Haematol. 2023. PMID: 37263719 No abstract available.
Loaded Leukosomes: A Smart Bomb to Halt Vascular Inflammation.
Csányi G, Lucas R, Annex BH. Csányi G, et al. Among authors: lucas r. Circ Res. 2020 Jan 3;126(1):38-40. doi: 10.1161/CIRCRESAHA.119.316249. Epub 2020 Jan 2. Circ Res. 2020. PMID: 31895661 Free PMC article. No abstract available.
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial.
Sanyal AJ, Lopez P, Lawitz EJ, Lucas KJ, Loeffler J, Kim W, Goh GBB, Huang JF, Serra C, Andreone P, Chen YC, Hsia SH, Ratziu V, Aizenberg D, Tobita H, Sheikh AM, Vierling JM, Kim YJ, Hyogo H, Tai D, Goodman Z, Schaefer F, Carbarns IRI, Lamle S, Martic M, Naoumov NV, Brass CA. Sanyal AJ, et al. Among authors: lucas kj. Nat Med. 2023 Feb;29(2):392-400. doi: 10.1038/s41591-022-02200-8. Epub 2023 Feb 16. Nat Med. 2023. PMID: 36797481 Free PMC article. Clinical Trial.
Decreases from baseline in ALT and HFF were greater with tropifexor versus placebo at week 12, with a relative decrease in least squares mean from baseline observed with all tropifexor doses for ALT (tropifexor 10-90-mug dose groups ranged from -10.7 to -16.5 U l(-1) versu …
Decreases from baseline in ALT and HFF were greater with tropifexor versus placebo at week 12, with a relative decrease in least squares mea …
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM, Dwivedi V, Senfeld JI, Cullum RL, Mill CP, Piazza JT, Bryant IN, Cook LJ, Miller ST, Lott JH 4th, Kelley CM, Knerr EL, Markham JA, Kaufmann DP, Jacobi MA, Shen J, Riese DJ 2nd. Lucas LM, et al. Pharmacol Rev. 2022 Jan;74(1):18-47. doi: 10.1124/pharmrev.121.000381. Pharmacol Rev. 2022. PMID: 34987087 Free PMC article. Review.
1,498 results